Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10899242 | 0.83 | KDM1A (0.46) | SMOGPR119KCNH2KDM4EAOC3 | |
| SCHEMBL19864978 | 0.82 | SMO (0.43) | SMOGPR119KDM4ECYP2C19AOC3 | |
| SCHEMBL12874114 | 0.82 | GPR119 (0.60) | GPR119KCNH2KDM4ECYP2C19GRM2 | |
| SCHEMBL24656049 | 0.81 | AOC3 (0.42) | SMOKDM4ECYP2C19AOC3LMNA | |
| SCHEMBL3828569 | 0.81 | SMO (0.42) | SMOKDM4ECYP2C19AOC3LMNA | |
| SCHEMBL3929507 | 0.81 | RIPK1 (0.46) | SMOKDM4ECYP2C19AOC3 | |
| SCHEMBL356595 | 0.81 | GPR119 (0.49) | SMOGPR119KCNH2KDM4ECYP2C19 | |
| SCHEMBL356301 | 0.81 | SMO (0.42) | SMOKDM4ECYP2C19AOC3CXCR3 | |
| SCHEMBL356575 | 0.81 | SMO (0.42) | SMOGPR119KDM4ECYP2C19AOC3 | |
| SCHEMBL15128622 | 0.81 | GPR119 (0.51) | GPR119KCNH2LMNAHTTGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556069-B1 | 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2556069-B1 | 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8415367-B2 | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415367-B2 | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415367-B2 | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2011127106-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127106-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251221-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| US-20110251221-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| EP-2185544-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | Metabolex Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | SMO 2090/4885GPR119 1/4885KCNH2 1920/4885 |
| US-20110251221-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR52 | SMO 437/4885GPR119 1/4885KCNH2 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.